Drugmaker Turing Suggests It Won't Cut List Price of Daraprim
- CEO Martin Shkreli previously promised to reduce drug's price
- Turing raised pill's price to $750 from $13.50 this year
Martin Shkreli: Daraprim Has Always Been Affordable
This article is for subscribers only.
Turing Pharmaceuticals AG, the drugmaker that raised the price of an anti-infective drug Daraprim by more than 5,000 percent, suggested that it won’t cut the drug’s list price, instead offering to negotiate discounts with hospitals.
“A reduction in Daraprim’s list price would not translate into a benefit for patients,” Nancy Retzlaff, Turing’s chief commercial officer, said in a statement. The company did say it would negotiate discounts with hospitals of as much as 50 percent.